June 17, 2014. Worcester, MA
Cureport, Inc. today announced that its nano formulation “ Double-Loaded Liposome for Non-Small Cell Lung Cancer Treatment” has been selected by Nanotechnology Characterization Laboratory (NCL) of National Cancer Institute (NCI) , operated by SAIC-Frederick (Frederick, Maryland), for NCL’s characterization support to advance the development of the formulation. The agreement is part of the NCI’s Cancer Nanotechnology Plan, which aims to accelerate the delivery of new products to cancer patients through the strategic application of advanced nanotechnologies and effective translational research partnerships.
The chemotherapy agent docetaxel and doxorubicin are widely used for the treatment of many types of human cancers with different mechanism. Using the proprietary nPortTM technology Cureport has developed a novel liposomal formulation, CPT319C, containing both agents in a single liposome particle to co-deliver of the two gents to the same tumor cells for an optimized synergic therapy.
In the event that there is a barrier in the blood to travel to the penis, cialis professional price allowing males to achieve an erection and maintain so for a longer time of lovemaking session. If you are currently struggling with erectile dysfunction, super viagra uk it can be time to search for the natural appendix which your exclamation can help the power. This helps cialis pharmacy persons who suffer from anemia. So, sildenafil discount for now, the bald community must settle for Propecia, the short-term solution for curing baldness. To meet with the restricting selection criteria of NCL, Cureport has demonstrated its advanced nPortTM platform nanotechnology for liposome manufacturing, comprehensive characterization package, promising animal study data, and product development plan.
These formed the basis of the decision made by the NCL’s scientific review committee for supporting the development of CPT319C.
“We are pleased the NCL accepted Cureport’s application to help us advance CPT319C toward the clinic,” said De-Min Zhu, president and chief executive officer of Cureport. “The combinational liposome technology has broad potential application in addressing therapeutic needs and CPT319C is our first approach.”